workshop agenda
Day 1: Tuesday, September 3, 2024
Session | TOPICS | TIME | SPEAKER/Affiliation |
---|---|---|---|
Guided Reading | Introduction of GRM (Video, Free Participation) | 0830-0850 | Kuo-Teng Hung (洪國登科長) Section Chief, Division of Medicinal Product, TFDA
|
Welcome Remarks | Welcome Remarks | 0900-0905 | Ching-Yi Lin (林靜儀次長) |
Opening | Opening Remarks & Group Photo |
0905-0920 | Shin-Hun Juang (莊聲宏署長) Director General, Taiwan Food and Drug Administration, TFDA Ayumi ENDOOffice Director, Office of Asia Training Center for Pharmaceutical and Medical Devices Regulatory Affairs, Pharmaceuticals and Medical Devices Regulatory Affairs, Pharmaceuticals and Medical Devices Agency (PMDA) Shinji Hatakeyama Leader, Regulations and Approvals Expert Working Group (RA-EWG), APAC, and Director, Asia Regulatory Affairs, Eisai Co., Ltd., Japan
|
Session 1 | Critical thinking and regulatory decision-making: Benefit-Risk Assessment in Regulatory Decision-Making for Market Authorization of Medicinal Products |
【Moderator】 Yi-Chu Lin (林意筑副組長) Deputy Director, Division of Medicinal Product, TFDA |
|
Regulatory:
● An overview of ICH M4E(R2) ● Experience sharing from perspectives of a clinical reviewer |
0920-0940
|
Chi-Hsun Chen (陳紀勳醫師) Senior Clinical Section Chief, Center for Drug Evaluation |
|
Academic: ● Structured frameworks to increase the transparency of the assessment of benefits and risks of medicines: Current status and possible future directions |
0940-1040
|
Lawrence Liberti Director,The D. K. Kim International Center for Regulatory Science, University of Southern California (USC) |
|
Break Time | 1040-1100 | ||
EMA: ● Current Practices for Benefit-Risk ● Assessment of Medicinal Products in EMA
|
1100-1200
|
Aaron Sosa Mejia Medical Oncologist, Chief Medical Officer, Danish Medicines Agency (DKMA), and Alternate CHMP member for Denmark, European Medicines Agency (EMA) |
|
Break | Lunch Time | 1200-1300 | |
Session 1 (continue) |
PMDA : Current Practices for Benefit-Risk Assessment of New Drugs in PMDA
|
1300-1330 |
Yuriko TAKEMURA Coordinator, Office of International Programs, PMDA
|
Industry : Industry Perspectives on Structured Benefit-Risk Assessment |
1330-1400 |
Masaaki Hayashi |
|
Panel Discussion:
|
1400-1435
|
CDE, Academic, EMA, PMDA, Industry | |
Break | Break Time ( Relocate to 3F conference room) | 1435-1455 | |
Session2 | Communication: Communication of Benefit and Risk for Pre-Market Approval and Post-Market Surveillance | 【Moderator】 Min Chen Former Acting Director of Pharmacovigilance , Office of Surveillance and Epidemiology, CDER, US FDA |
|
● Introductory Lectures: Overview of Communication Mechanisms - Regulators’ Aspects - Industry Aspects |
1455-1535
|
【Speaker 】 Min Chen
|
|
● Group Discussion | 1535-1635 |
||
● Group Presentation | 1635-1735 |
||
● Take Home Message | 1735-1740 |
||
Break | Break Time (Relocate to 1F Entrence for taking Shuttle Bus) |
||
Welcome Reception | 1830-2030 |
* The program may be subjected to change.
Day 2: Wednesday, September 4, 2024
Session | TOPIC | TIME | SPEAKER |
---|---|---|---|
Session 3 | Status of Implementation of GRM in the Economies |
【Moderator】 |
|
Status of Implementation of GRM in the Economies | 0900-0930 | Representatives from 3 economies | |
Session 4 | Planning of Application | 【Moderator】 |
|
● Ice breaker ● Introductory Lectures - Planning for a successful submission to expedite early approval - How to develop a good Generic registration plan? |
0930-1030 | 【Speaker】 |
|
● Group Discussion | 1045-1135 | ||
● Group Presentation | 1135-1225 | ||
● Take Home Message | 1225-1230 | ||
Break | Lunch Time | 1230-1330 | |
Session 5 | Preparation of Application Dossier: Think about preparing your current and future applications |
【Moderator】 |
|
● Introductory Lectures - Current Environment - Preparation of Application Dossier based on GsubP |
1330-1430 | 【Speaker】 |
|
● Group Discussion | 1430-1520 | ||
● Group Presentation | 1535-1635 | ||
● Take Home Message | 1635-1640 | ||
* The program may be subjected to change.
Day 3: Thursday, September 5, 2024
Session | TOPIC | TIME | SPEAKER |
---|---|---|---|
Session 6 | Conducting the Review in Regenerative Medicine | 【Moderator】 Shinichi Noda Deputy Review Director, Office of Cellular and Tissue-based Products, PMDA |
|
Regulatory Updates for Regenerative Medicine in Taiwan | 0900-0920 | Yueh-Tung Tsai (蔡岳橦技正) Technical Specialist, Division of Medicinal Product, TFDA |
|
Regulatory Updates for Regenerative Medicine in Japan | 0920-0940 | Jun Matsumoto Review Director, Office of Cellular and Tissue-based Products, PMDA |
|
GRevP of Quality part regarding CMC consideration | 0940-1000 | Shinichi Noda Deputy Review Director, Office of Cellular and Tissue-based Products, PMDA |
|
Break Time | 1000-1015 | ||
GRevP of Quality part regarding Clinical consideration | 1015-1035 | Shinichi Noda Deputy Review Director, Office of Cellular and Tissue-based Products, PMDA |
|
Industry | 1035-1055 | Yayoi Kitawaki Head, Neuroscience, GTx Development Unit Novartis Pharma K.K. |
|
Q&A | 1055-1115 | TFDA, PMDA, Industry | |
Break | Break Time | 1115-1130 | |
Closing Remarks | Certificate Award Ceremony | 1130-1145 | Shin-Hun Juang (莊聲宏署長) Director General, Taiwan Food and Drug Administration, TFDA |
Closing Remarks | 1145-1200 | Shin-Hun Juang (莊聲宏署長) Director General, Taiwan Food and Drug Administration, TFDA |
* The program may be subjected to change.